Serina Therapeutics, Inc.(SER)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Serina Therapeutics, Inc. (SER) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SER at 8.7/100 on a 32-signal composite quality model, placing it at rank #2,924 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Serina Therapeutics, Inc. reports net income of $-6.4M, free cash flow of $-6.7M. Top institutional holders of SER by reported 13-F value include Sio Capital Management, VANGUARD CAPITAL MANAGEMENT, Waverly Advisors, based on the most recent SEC filings. SER trades on the NYSE exchange and files with the SEC under CIK 1708599. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SER daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Serina Therapeutics, Inc. directly from SEC EDGAR.
AI Quality Score
8.7/100
AI Rank
#2,924
Revenue
$0.00
Net Income
$-6.4M
Free Cash Flow
$-6.7M
SER key financials by period
Serina Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$130.0K
$-19.2M
—
FY 2024
10-K
$56.0K
$-11.1M
—
FY 2023
10-K
$3.2M
$5.3M
-99.2%
FY 2022
10-K
$34.0K
$-10.5M
—
FY 2021
10-K
$144.0K
$-8.7M
—
FY 2020
10-K
$361.0K
$-10.9M
—
Institutions holding SER
Institutional investors reporting a position in Serina Therapeutics, Inc. on SEC Form 13F.
